tigecycline for injection (50mg)
product
tigecycline for injection (50mg)
indications
this product is suitable for patients over 18 years old have the sensitive strains caused by specific bacterial infections in the following cases:
with complicated intra-abdominal infections : from citrobacter freundii , enterobacter cloacae , escherichia coli, klebsiella oxytoca , klebsiella pneumoniae , enterococcus faecalis ( vancomycin- susceptible strains only ) , staphylococcus aureus ( methicillin-sensitive strains and methicillin resistant strains ) , streptococcus anginosus ( including buccal pharyngeal inflammation streptococcus , streptococcus and constellations intermediate streptococcus ) , bacteroides fragilis , bacteroides pleomorphic , simplex bacteroides , bacteroides ordinary , clostridium perfringens and peptostreptococcus caused by tiny .
complicated skin and soft tissue infections : there are escherichia coli , enterococci ( vancomycin- susceptible strains ) , staphylococcus aureus ( methicillin-sensitive strains and methicillin resistant strains ) , streptococcus agalactiae , anginosus chain bacteria ( including streptococcus anginosus , streptococcus and constellations intermediate streptococcus ) , streptococcus pyogenes , enterobacter cloacae , klebsiella pneumoniae , and bacteroides fragilis were caused
community-acquired pneumonia: streptococcus pneumoniae (penicillin- susceptible strains), haemophilus influenzae (within β- lactamase negative isolates), and legionella pneumophila bacteria and other disease caused by, including concurrent bacteremia.
in order to isolate, identify pathogens and their sensitivity to clear tigecycline should specimen’s suitable specimens for bacteriological testing. before these results are not yet known, this product can be used as an empiric immunotherapy.
in order to reduce the appearance of drug-resistant bacteria and maintain the effectiveness of the goods and other antibacterial drugs, this product should be used only for the treatment of confirmed or highly suspected bacterial infections caused. once informed of culture and sensitivity test results, should be selected or adjusted according to the antibiotic therapy. in the absence of such information, the choice of empirical therapy based on local epidemiology and susceptibility patterns.
only known and suspected use of other antimicrobial agents which not allowed by fda.